Health Care • Biotechnology: Pharmaceutical Preparations
$4.11 ▼ -0.12
(-2.84%)
MKT CAP: $176.0M • VOL: 91.5K
52W L $2 52W H $5
ROARABLE / RQD
D- • 41/100
PIOTROSKI
3 / 9
ORMP // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $2.0M | $0 | $1.3M |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $13.0K | — | — |
| Gross Margin % | 0.7% | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$15.1M | -$12.8M | -$15.8M |
| Operating Margin % | -80.0% | — | -80.0% |
| Net Income (GAAP) | $75.3K | -$15.9K | $5.1K |
| EBITDA (Normalized) | -$15.1M | -$12.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$9.1M | -$8.4M | -$10.3M |
| Capital Expenditures (CapEx) | $9.0K | $18.0K | — |
| Free Cash Flow (FCF) | -$9.2M | -$8.4M | -$10.3M |
| FCF Margin % | -80.0% | — | -80.0% |
| Return on Invested Capital (ROIC %) | -7.8% | -11.0% | — |
| Cash & Short-Term Equivalents | $45.9M | $54.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $199.7M | $146.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ORMP.